Veracyte (VCYT) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Veracyte

NasdaqGM•Healthcare•Diagnostics & Research

$38.50-1.64(-0.04%)Pre-market

Market Cap

$3.18B

P/E

27.8x

P/S

5.7x

P/B

2.3x

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

How this company scores

ExcellentMetricSide Score: 81/100

Strongest: Cash & Earnings Quality (25/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability18/25

Growth23/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality25/25

Strengths

Growing revenueRising free cash flowStrong marginsRising earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 27.8x5y range 27.5x – 128.6x

Currently below its 7-quarter median.

P/S · 5.7x5y range 4.2x – 16.9x

Currently near its 20-quarter median.

P/B · 2.3x5y range 1.1x – 2.9x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Share Dilution

Watch

Shares outstanding rose 3.8% — mild dilution. Compare to earnings growth to assess the net per-share impact.

Price & Volume

Market Cap $3.18B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $561.90M
Q. Revenue: $150.32M
TTM EBITDA: $126.60M
TTM Op. Income: $105.77M
Q. Op. Income: $22.98M
TTM Net Income: $114.48M
Q. Net Income: $25.49M
EPS: $0.32
Shares Out.: $79.97M

$561.90M in TTM revenue grew 17.3% YoY, reaching $150.32M last quarter. TTM EBITDA of $126.60M and TTM operating income of $105.77M show growth is flowing through to the bottom line. TTM net income of $114.48M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 72.2%
EBITDA Margin: 18.5%
Op. Margin: 15.3%
Net Margin: 17.0%

Op. margin of 15.3% is up 19.3% YoY — cost efficiency is improving. Net margin at 17.0% and gross margin of 72.2% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 27.8x
P/S Ratio: 5.7x
P/B Ratio: 2.3x

At 27.8x P/E, the stock trades within typical market levels. P/S of 5.7x and P/B of 2.3x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 65% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.49B
Cash: $299.52M
Long-Term Debt: N/A
Book Value: $1.39B
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $45.83M
TTM Free Cash Flow: $165.99M
FCF Margin: 29.5%
FCF / Net Income: 1.4

TTM FCF of $165.99M on $45.83M in operating cash flow. The FCF / Net Income ratio of 1.4x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 7 consecutive quarters — an improving trend.